Találati lista | Tudóstér

001-es BibID:	BIBFORM071387
Első szerző:	Harangi Mariann (belgyógyász, endokrinológus)
Cím:	HDL subfraction distribution and HDL function in untreated dyslipidemic patients / Harangi Mariann, Szentpéteri Anita, Nádró Bíborka, Lőrincz Hajnalka, Seres Ildikó, Páll Dénes, Paragh György
Dátum:	2017
ISSN:	2574-1209
Megjegyzések:	Aim: The protective role of high-density lipoprotein (HDL) against atherosclerosis is wellknown. However, both structural and functional changes of the HDL particles may affect itsprotective efficacy. Increased levels of HDL-associated myeloperoxidase (MPO) and decreasedHDL-linked paraoxonase-1 (PON1) activity have been reported in dyslipidemic patients. Somechanges in HDL subfraction distributions were also studied previously, but data on structuraland functional changes in dyslipidemia are not complete. Therefore, the authors aimed toevaluate these qualitative and quantitative markers of HDL in dyslipidemic patients andhealthy control subjects. Methods: Anthropometric parameters, serum levels of lipoproteinsand MPO, as well as PON1 activities were investigated in 81 untreated dyslipidemic patientsand in 32 healthy gender-matched controls. Additionally, HDL subfractions were detectedby an electrophoretic method on polyacrylamide gel (Lipoprint). Results: Significantlyhigher glucose, hemoglobin A1c, total cholesterol, low-density lipoprotein-cholesterol,triglyceride, lipoprotein(a), apolipoprotein B, C-reactive protein, and MPO levels were foundin patients compared to the healthy subjects. There were no significant differences in PON1paraoxonase and arylesterase activities between the two study groups, but MPO/PON1 ratiowas significantly higher in patients. There was a shift towards the smaller HDL subfractions,but only the intermediate HDL ratio was significantly lower in patients compared to controls.Conclusion: The results highlight the importance of HDL-associated pro- and antioxidantenzymes suggesting the possible clinical benefit of MPO/PON1 calculation and confirm thatquantification of HDL-C level alone provides limited data regarding HDL's cardioprotectiveeffect. Calculation of MPO/PON1 ratio may be a useful cardiovascular marker in dyslipidemia.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban subfraction paraoxonase myeloperoxidase dyslipidemia high-density lipoprotein
Megjelenés:	Vessel Plus. - 1 (2017), p. 166-173. -
További szerzők:	Szentpéteri Anita (1988-) (biológus) Nádró Bíborka (1992-) (általános orvos) Lőrincz Hajnalka (1986-) (biológus) Seres Ildikó (1954-) (biokémikus) Páll Dénes (1967-) (belgyógyász, kardiológus) Paragh György (1953-) (belgyógyász)
Pályázati támogatás:	GINOP-2.3.2-15-2016-00062 GINOP OTKA-115723 OTKA
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM103908
Első szerző:	Nádró Bíborka (általános orvos)
Cím:	Serum progranulin level in patients with newly diagnosed untreated familial hypercholesterolemia / Nádró B., Lőrincz H., Juhász L., Szentpéteri A., Sztanek F., Seres I., Páll D., Fülöp P., Paragh G., Harangi M.
Dátum:	2022
ISSN:	0021-9150
Megjegyzések:	Background and Aims : Familial hypercholesterolemia (FH) is a monogenic form of severe hypercholesterolemia, characterized by elevated total cholesterol and low-density lipoprotein-cholesterol concentrations that, if left untreated, is associated with early onset of atherosclerosis. Progranulin (PGRN) is a recently discovered growth factor with many biological functions. PGRN has anti-inflammatory properties because it inhibits neutrophil degranulation and blocks tumor necrosis factor ? transmission, therefore, might be anti-atherogenic. To date, serum level of PGRN in patients with FH has not been studied. Methods: Eighty-one newly diagnosed, untreated patients with FH and 32 healthy control subjects were involved in our study. Serum PGRN levels were determined by ELISA. We diagnosed FH using the Dutch Lipid Clinic Network criteria. Results: We could not find significant difference in serum PGRN levels between FH patients and healthy controls (37.66?9.75 vs. 38.43?7.74 ng/mL, ns.). However, we found significant positive correlations between triglyceride, C-reactive protein (CRP), and PGRN levels (p<0.01 and p<0.01, respectively), while significant negative correlation was found between high-density lipoprotein cholesterol (HDL-C) and PGRN levels (p<0.05) both in the whole study population and in FH patients. Conclusions: Strong correlations between HDL-C, CRP and PGRN levels suggest that PGRN may exerts its anti-atherogenic effect in FH patients by alteration in HDL-C level by amelioration of inflammatory processes. Further studies on larger study populations are needed to clarify the underlying mechanisms. Funding: This presentation was supported by the Bridging Fund (Faculty of Medicine, University of Debrecen) and PD124126 project.
Tárgyszavak:	Orvostudományok Egészségtudományok idézhető absztrakt folyóiratcikk atherosclerosis familial hypercholesterolemia progranulin lipoprotein inflammation
Megjelenés:	Atherosclerosis. - 355 (2022), p. e248. -
További szerzők:	Lőrincz Hajnalka (1986-) (biológus) Juhász Lilla (1990-) (általános orvos) Szentpéteri Anita (1988-) (biológus) Sztanek Ferenc (1982-) (orvos) Seres Ildikó (1954-) (biokémikus) Páll Dénes (1967-) (belgyógyász, kardiológus) Fülöp Péter (1974-) (belgyógyász, endokrinológus, lipidológus) Paragh György (1953-) (belgyógyász) Harangi Mariann (1974-) (belgyógyász, endokrinológus)
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM094676
Első szerző:	Nádró Bíborka (általános orvos)
Cím:	Effects of alpha-lipoic acid treatment on serum progranulin levels and inflammatory markers in diabetic neuropathy / Bíborka Nádró, Hajnalka Lőrincz, Ágnes Molnár, Anita Szentpéteri, Eszter Zöld, Ildikó Seres, Dénes Páll, György Paragh, Péter Kempler, Mariann Harangi, Ferenc Sztanek
Dátum:	2021
ISSN:	0300-0605
Megjegyzések:	Objectives: Progranulin (PGRN) is a secreted growth factor that helps to regulate neuronal survival by blocking tumor necrosis factor-alpha (TNFa) receptors. The antioxidant alpha-lipoic acid (ALA) is used in diabetic neuropathy to improve nerve conduction and relieve neuropathic pain, but its effects on PGRN levels have not yet been elucidated. Methods: In this prospective study, 54 patients with type 2 diabetes and peripheral neuropathy received 600 mg of ALA daily for 6 months. Twenty-four patients with diabetes without neuropathy were also included in the study. Serum PGRN and TNFa levels were determined using enzyme-linked immunosorbent assays. In addition, current perception threshold (CPT) testing was used to assess sensory neuropathy. Results: After ALA treatment, serum PGRN levels were significantly increased and CPT values were significantly improved. Furthermore, there were significant positive correlations among TNFa, ICAM-1, and PGRN levels both before and after ALA treatment. A significant negative correlation was observed between the improvements in CPT and the PGRN levels. Furthermore, ICAM-1 levels were an independent predictor of PGRN levels. Conclusions: Changes in serum PGRN levels indicate that ALA treatment may have beneficial effects on endothelial function and neuronal inflammation.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk diabetic neuropathy cardiac autonomic neuropathy progranulin intercellular adhesion molecule-1 alpha-lipoic acid tumor necrosis factor-alpha type 2 diabetes
Megjelenés:	Journal of International Medical Research. - 49 : 5 (2021), p. 1-13. -
További szerzők:	Lőrincz Hajnalka (1986-) (biológus) Molnár Ágnes (1972-) (gyógytornász) Szentpéteri Anita (1988-) (biológus) Zöld Eszter (1988-) (szemész) Seres Ildikó (1954-) (biokémikus) Páll Dénes (1967-) (belgyógyász, kardiológus) Paragh György (1953-) (belgyógyász) Kempler Péter (1954-) (belgyógyász, diabetológus) Harangi Mariann (1974-) (belgyógyász, endokrinológus) Sztanek Ferenc (1982-) (orvos)
Pályázati támogatás:	EFOP-3.6.2-16-2017-00009 EFOP OTKA-115723 OTKA
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: